Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 1/20 | 0.59 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.59 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.59 |
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.54 |
| ▸ | USP2 | O75604 | 1/20 | 0.54 |
| ▸ | OPRK1 | P41145 | 4/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.52 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.50 |
| ▸ | ALPL | P05186 | 1/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.48 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.48 |
| ▸ | LTA4H | P09960 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| N-Benzyltropan-4-Ol SCHEMBL911838 | 1.00 | CHRM2 (0.59) | CHRM2CHRM4CHRM5LMNAKMT2A | |
| N-Benzyltropan-4-Ol SCHEMBL910594 | 1.00 | CHRM2 (0.59) | CHRM2CHRM4CHRM5LMNAKMT2A | |
| SCHEMBL16766586 | 0.93 | CHRM2 (0.62) | CHRM2CHRM4CHRM5LMNAKMT2A | |
| SCHEMBL13993541 | 0.93 | CHRM2 (0.62) | CHRM2CHRM4CHRM5LMNAKMT2A | |
| SCHEMBL16766562 | 0.93 | CHRM2 (0.62) | CHRM2CHRM4CHRM5LMNAKMT2A | |
| SCHEMBL694189 | 0.93 | CHRM2 (0.62) | CHRM2CHRM4CHRM5LMNAKMT2A | |
| SCHEMBL4870895 | 0.85 | CHRM2 (0.60) | CHRM2CHRM4CHRM5LMNAKMT2A | |
| Ammonia Solution, Strong SCHEMBL8187341 | 0.83 | CHRM2 (0.58) | CHRM2CHRM4CHRM5LMNAKMT2A | |
| SCHEMBL5728905 | 0.83 | CHRM2 (0.58) | CHRM2CHRM4CHRM5LMNAKMT2A | |
| SCHEMBL1723411 | 0.83 | CHRM2 (0.58) | CHRM2CHRM4CHRM5LMNAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115093549-A | Polythiophene with side chain containing ABNO, and preparation method and application thereof | 浙江吉泰新材料股份有限公司 | 2022-09-23 | — | — | CN | claimed |
| CN-115073714-A | Polycarbazole with side chain containing nitroxide free radical and preparation method and application thereof | 浙江吉泰新材料股份有限公司 | 2022-09-20 | — | — | CN | claimed |
| WO-2025095021-A1 | TETRAZENE COMPOUND, TETRAZENE RADICAL SALT COMPOUND, TETRAZENE-TYPE ALCOHOL OXIDATION CATALYST, TETRAZENE RADICAL SALT-TYPE ALCOHOL OXIDATION CATALYST, AND ALCOHOL OXIDATION METHOD USING SAME | 国立大学法人東北大学 | 2025-05-08 | — | — | WO | disclosed |
| CN-115093549-A | Polythiophene with side chain containing ABNO, and preparation method and application thereof | 浙江吉泰新材料股份有限公司 | 2022-09-23 | — | — | CN | disclosed |
| CN-115073714-A | Polycarbazole with side chain containing nitroxide free radical and preparation method and application thereof | 浙江吉泰新材料股份有限公司 | 2022-09-20 | — | — | CN | disclosed |
| CN-115073714-A | Polycarbazole with side chain containing nitroxide free radical and preparation method and application thereof | 浙江吉泰新材料股份有限公司 | 2022-09-20 | — | — | CN | disclosed |
| US-20210024493-A1 | Diamide Compounds Having Muscarinic Receptor Antagonist and Beta2 Adrenergic Receptor Agonist Activity | THERAVANCE RESPIRATORY COMPANY, LLC | 2021-01-28 | — | — | US | disclosed |
| US-10836744-B2 | Diamide compounds having muscarinic receptor antagonist and β2 adrenergic receptor agonist activity | THERAVANCE RESPIRATORY COMPANY, LLC (US) | 2020-11-17 | — | — | US | disclosed |
| US-20200165223-A1 | Diamide Compounds Having Muscarinic Receptor Antagonist and Beta2 Adrenergic Receptor Agonist Activity | THERAVANCE RESPIRATORY COMPANY, LLC | 2020-05-28 | — | — | US | disclosed |
| US-10590107-B2 | Diamide compounds having muscarinic receptor antagonist and Beta2 adrenergic receptor agonist activity | THERAVANCE RESPIRATORY COMPANY, LLC (US) | 2020-03-17 | — | — | US | disclosed |
| US-20190300504-A1 | Diamide Compounds Having Muscarinic Receptor Antagonist and Beta2 Adrenergic Receptor Agonist Activity | THERAVANCE RESPIRATORY COMPANY, LLC | 2019-10-03 | — | — | US | disclosed |
| US-7868017-B2 | 9-azabicyclo[3.3.1]nonane derivatives | N.V. ORGANON (NL) | 2011-01-11 | — | — | US | disclosed |
| WO-2010123766-A1 | DIAMIDE COMPOUNDS HAVING MUSCARINIC RECEPTOR ANTAGONIST AND β2 ADRENERGIC RECEPTOR AGONIST ACTIVITY | THERAVANCE, INC. (US) | 2010-10-28 | — | — | WO | disclosed |
| US-20100273755-A1 | DIAMIDE COMPOUNDS HAVING MUSCARINIC RECEPTOR ANTAGONIST AND BETA2 ADRENERGIC RECEPTOR AGONIST ACTIVITY | THERAVANCE BIOPHARMA R&D IP, LLC | 2010-10-28 | — | — | US | disclosed |
| EP-1979318-A1 | AMIDO COMPOUNDS AND THEIR USE AS PHARMACEUTICALS | Incyte Corporation (US) | 2008-10-15 | — | — | EP | disclosed |
| EP-1934212-A1 | 9-AZABICYCLO [3 . 3 . 1]NONANE DERIVATIVES AS MONOAMINE REUPTAKE INHIBITORS | N.V. Organon (NL) | 2008-06-25 | — | — | EP | disclosed |
| US-20070197530-A1 | Amido compounds and their use as pharmaceuticals | INCYTE CORPORATION | 2007-08-23 | — | — | US | disclosed |
| WO-2007089683-A1 | AMIDO COMPOUNDS AND THEIR USE AS PHARMACEUTICALS | INCYTE CORPORATION (US) | 2007-08-09 | — | — | WO | disclosed |
| US-20070112019-A1 | 9-Azabicyclo[3.3.1]nonane derivatives | N.V. ORGANON (NL) | 2007-05-17 | — | — | US | disclosed |
| WO-2007039563-A1 | 9-AZABICYCLO [3 . 3 . 1] NONANE DERIVATIVES AS MONOAMINE REUPTAKE INHIBITORS | N.V. ORGANON (NL) | 2007-04-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190300504-A1 | Diamide Compounds Having Muscarinic Receptor Antagonist and Beta2 Adrenergic Receptor Agonist Activity | ADRB2, ADRB1, ADRA2B | CHRM2 11/4885CHRM4 31/4885CHRM5 23/4885 |
| US-10836744-B2 | Diamide compounds having muscarinic receptor antagonist and β2 adrenergic receptor agonist activity | ADRB2, ADRB1, ADRA2A | CHRM2 11/4885CHRM4 26/4885CHRM5 20/4885 |
| US-20210024493-A1 | Diamide Compounds Having Muscarinic Receptor Antagonist and Beta2 Adrenergic Receptor Agonist Activity | ADRB2, ADRB1, ADRA2B | CHRM2 9/4885CHRM4 25/4885CHRM5 19/4885 |
| US-10590107-B2 | Diamide compounds having muscarinic receptor antagonist and Beta2 adrenergic receptor agonist activity | ADRB2, ADRB1, ADRA2B | CHRM2 11/4885CHRM4 31/4885CHRM5 23/4885 |
| US-20070197530-A1 | Amido compounds and their use as pharmaceuticals | HSD11B1, HSD17B11, CYP11B1 | CHRM2 4518/4885CHRM4 4766/4885CHRM5 4551/4885 |
| US-20070112019-A1 | 9-Azabicyclo[3.3.1]nonane derivatives | AZI2, TPMT, TET3 | CHRM2 1569/4885CHRM4 2796/4885CHRM5 1393/4885 |
| US-20200165223-A1 | Diamide Compounds Having Muscarinic Receptor Antagonist and Beta2 Adrenergic Receptor Agonist Activity | ADRB2, ADRB1, ADRA2B | CHRM2 11/4885CHRM4 31/4885CHRM5 23/4885 |
| US-20100273755-A1 | DIAMIDE COMPOUNDS HAVING MUSCARINIC RECEPTOR ANTAGONIST AND BETA2 ADRENERGIC RECEPTOR AGONIST ACTIVITY | ADRB2, ADRB1, ADRA2A | CHRM2 10/4885CHRM4 27/4885CHRM5 17/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.